Article Sidebar

PDF
Date Published: 28/06/2025
Abstract Views: 1
Views PDF: 2
DOI: https://doi.org/10.56535/jmpm.v50i5.1215
Issue
Vol. 50 No. 5 (2025): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 5 - 2025
Section
Articles
How to Cite
Quan, T. N., Nghiêm, Đ. T., Nguyễn, T. H., & Nguyễn, Q. T. (2025). OUTPATIENT TREATMENT OUTCOMES OF ALLERGIC RHINITIS WITH INTRANASAL BUDESONIDE AT MILITARY HOSPITAL 103. Journal of Military Pharmaco-medicine, 50(5), 221-228. https://doi.org/10.56535/jmpm.v50i5.1215

OUTPATIENT TREATMENT OUTCOMES OF ALLERGIC RHINITIS WITH INTRANASAL BUDESONIDE AT MILITARY HOSPITAL 103

Quan Thanh Nam1, , Nghiêm Đức Thuận1, Nguyễn Thị Hòa2, Quyết Thắng Nguyễn1
1 Bệnh viện Quân y 103, Học viện Quân y
2 Học viện Chính trị

Main Article Content

Abstract

Objective: To evaluate the improvement in clinical symptoms and quality of life (QoL) in patients with allergic rhinitis (AR) undergoing outpatient treatment with intranasal Budesonide. Methods: A prospective, case-by-case descriptive study was conducted on 61 patients diagnosed with AR at Military Hospital 103 from October 2023 to December 2024. Results: House dust was the most common allergen, accounting for 83.6% of cases. After three months of treatment: 77.0% of patients had complete resolution of nasal itching; 73.8% had no further sneezing episodes; 78.7% experienced cessation of rhinorrhea; and 45.9% achieved full relief from nasal congestion. Additionally, 72.1% exhibited normalization of the nasal mucosa, and 83.6% showed restored inferior turbinate morphology. The mean QoL score improved significantly from 2.2 ± 0.6 to 0.8 ± 0.2, with a mean reduction of 1.4 ± 0.5 points, reflecting an overall improvement rate of 63.6%. Conclusion: Intranasal Budesonide showed marked improvement in both clinical symptoms and quality of life in patients with allergic rhinitis after three months of treatment.

Article Details

Keywords

Allergic rhinitis,, intranasal spray

References

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN* and AllerGen**. Allergy. 2008; 63:8-160.
2. Bousquet PJ, Demoly P, Devillier P, et al. Impact of allergic rhinitis symptoms on quality of life in primary care. International Archives of Allergy and Immunology. 2013; 160(4):393-400.
3. Ellis AK, Soliman M, Steacy L, et al. Nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies. The Allergic Rhinitis - Clinical Investigator Collaborative (AR-CIC). 2015; 11(1):16.
4. Juniper EF, Guyatt GH, Griffith LE, et al. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Journal of Allergy and Clinical Immunology. 1996; 98(4):843-845.
5. Rak S, Yang WH, Pedersen MR, et al. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: A double-blind, randomised study. Quality of Life Research. 2006; 16(2):191-201.
6. Nguyễn Thanh Thanh. Tổng quan luận điểm về các loại corticoid xịt mũi điều trị viêm mũi dị ứng. Tạp chí Y học Việt Nam. 2025; 546(3):253-258.
7. Tăng Xuân Hải. Thực trạng viêm mũi dị ứng và hiệu quả can thiệp điều trị fluticasone ở học sinh trung học cơ sở thành phố Vinh tỉnh Nghệ An năm 2014 - 2016. Luận án Tiến sỹ Y học. Đại học Y Dược Hải Phòng. 2019.
8. Gendeh HS, Hamizan AW, Husain S. The efficacy of elonide nasal corticosteroids in managing allergic rhinitis: A randomized, double-blinded trial. J Clin Med. 2024; 13(7):1883.
9. Passali D, Bellussi LM, Gregori D, et al. Nasal obstruction as a key symptom in allergic rhinitis: Efficacy and safety of a medical device in children. Otolaryngologia Polska. 2012; 66(4):249-253.